Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Measured Wealth Private Client Group LLC

Measured Wealth Private Client Group LLC grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 47.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,855 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,554 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Jazz Pharmaceuticals were worth $515,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Picton Mahoney Asset Management boosted its holdings in Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. SVB Wealth LLC acquired a new position in Jazz Pharmaceuticals in the first quarter valued at approximately $36,000. Hantz Financial Services Inc. grew its position in Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares during the period. Geneos Wealth Management Inc. grew its position in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the period. Finally, Brooklyn Investment Group raised its position in Jazz Pharmaceuticals by 411.1% in the first quarter. Brooklyn Investment Group now owns 552 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 444 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.7%

Shares of Jazz Pharmaceuticals stock opened at $176.92 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The company has a market capitalization of $10.75 billion, a P/E ratio of -26.29, a P/E/G ratio of 8.49 and a beta of 0.29. The company has a 50 day moving average of $142.91 and a 200 day moving average of $124.48.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. UBS Group reiterated a “neutral” rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Bank of America boosted their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Finally, JPMorgan Chase & Co. dropped their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $195.67.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 5,500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the sale, the director directly owned 8,893 shares of the company’s stock, valued at $1,608,387.98. The trade was a 38.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Iannone sold 7,159 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $168.26, for a total value of $1,204,573.34. Following the transaction, the executive vice president directly owned 72,628 shares of the company’s stock, valued at approximately $12,220,387.28. This represents a 8.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 50,893 shares of company stock worth $8,559,699. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.